NCT06723080招募中3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 480
- 试验地点
- 1
- 主要终点
- Proportion of subjects achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75) from Baseline at Week 16
研究概览
简要总结
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(1）The patient understands and voluntarily signs the Informed Consent Form (ICF), and has the willingness and ability to complete the regular visits,treatment plans, laboratory tests and other experimental procedures required by the program. (2) Male or female patients aged ≥18 and ≤75 years at the time of signing the ICF. (3) Meet Hanifin-Rajka diagnostic criteria at screening and have atopic dermatitis （AD) symptoms for at least 1 year prior to baseline. (4) At screening and baseline, meets criteria for moderately severe AD based on the investigator's assessment of 3 of the following:Eczema area and severity index (EASI) score ≥12;Psoriasis Area Severity Index (IGA) score ≥3;AD involvement in ≥10% of the Body Surface Area (BSA). (5) Recent (within 1 year prior to screening) topical treatment for AD with inadequate or intolerant clinical response, as determined by the investigator
排除标准
- •(1) Inability to swallow the test drug or refractory nausea and vomiting, malabsorption, extracorporeal biliary shunt, or the presence of a gastrointestinal disorder (e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome) or other malabsorption condition that interferes with the absorption of the drug; (2) Current or history of lymphoproliferative disorders or presence of signs or symptoms suggestive of possible lymphoproliferative disorders of lymphoid tissue, including lymphadenopathy or splenomegaly; malignancies of any kind, or a history of any malignancy within the 5 years prior to Screening (except for completely resected carcinoma in situ of the cervix or non-metastatic squamous cell or basal cell carcinoma of the skin or papillary carcinoma of the thyroid gland); (3) Patients with prior thromboembolism (including deep vein thrombosis, pulmonary embolism, arterial thrombosis, etc.) or other high-risk groups prone to thromboembolism; (4) Patients with a history of herpes virus infection within the last 1 month or those with recurrent episodes of herpes zoster (≥2), disseminated herpes zoster, disseminated herpes simplex, or those for whom herpes zoster or herpes simplex infections cannot be excluded at this time;
研究组 & 干预措施
VC005 high dose group
Experimental
干预措施: VC005 high dose group (Drug)
VC005 placebo group
Placebo Comparator
干预措施: VC005 Placebo group (Drug)
VC005 low dose group
Experimental
干预措施: VC005 low dose group (Drug)
结局指标
主要结局
Proportion of subjects achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75) from Baseline at Week 16
时间窗: week 16
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of MW031 in PMO SubjectsOsteoporosis, PostmenopausalNCT05215977Mabwell (Shanghai) Bioscience Co., Ltd.448
已完成
3 期
Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)COVID-19NCT05716425Zhejiang ACEA Pharmaceutical Co. Ltd.1,218
招募中
3 期
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisPsoriasisNCT06477237Huabo Biopharm Co., Ltd.400
进行中（未招募）
3 期
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic ArthritisPsoriatic ArthritisNCT06640257Suzhou Suncadia Biopharmaceuticals Co., Ltd.208
已完成
3 期
Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19COVID-19NCT05679479Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd108